Endogenous spacing enables co-processing of microRNAs and efficient combinatorial RNAi

Area of Science:

• Molecular Biology
• Gene Therapy
• Cancer Research

Background:

• Combinatorial RNA interference (RNAi) offers potential for targeting complex diseases.
• Existing shRNA delivery systems face limitations in simultaneous expression and in vivo stability.
• MicroRNA (miRNA) clusters provide a natural model for co-expressing multiple RNA molecules.

Purpose of the Study:

• To develop a novel microRNA-embedded shRNA system (Multi-miR) for simultaneous expression of multiple shRNAs.
• To create advanced all-in-one vectors with enhanced doxycycline-inducible activation and in vivo stability.
• To demonstrate the efficacy of Multi-miR in preclinical cancer models, including glioblastoma and KRAS-mutant cancer.

Main Methods:

• Engineered a microRNA-embedded shRNA system (Multi-miR) for co-expression of 3-4 shRNAs from a single promoter.
• Developed all-in-one vectors with improved doxycycline-inducible control and resistance to shRNA inactivation.
• Utilized the Multi-miR system for intracranial shRNA delivery in a glioblastoma model.
• Applied the platform to target the RAF signaling node in a KRAS-mutant mouse cancer model.

Main Results:

• Multi-miR enables simultaneous expression of multiple shRNAs without loss of activity, achieving robust combinatorial RNAi.
• The developed vectors exhibit enhanced sensitivity to doxycycline induction in vitro and stability in vivo.
• Intracranial delivery of shRNAs using Multi-miR was demonstrated in a glioblastoma model.
• Targeting the RAF signaling node via combinatorial synthetic lethality with Multi-miR efficiently suppressed tumor growth in a KRAS-mutant cancer model.

Conclusions:

• Multi-miR represents a powerful platform for combinatorial RNAi, enabling simultaneous and active expression of multiple shRNAs.
• The enhanced vector system offers improved control and stability for in vivo gene silencing applications.
• This technology shows significant promise for developing effective combinatorial therapies against challenging cancers like glioblastoma and KRAS-mutant tumors.